title: Intracranial hemorrhage during dabigatran treatment.
abstract: BACKGROUND
  The incidence of intracranial bleeding during dabigatran treatment is lower than that during warfarin treatment. The characteristics of intracranial hemorrhage during dabigatran therapy, however, remain unclear.
  
  
  RESULTS
  The clinical data and treatment summaries of 9 intracranial bleeds that developed during dabigatran treatment in 8 patients with non-valvular atrial fibrillation were retrospectively reviewed. Five patients had small-moderate subdural hematomas, 2 had intracerebral hemorrhage and 1 had traumatic subarachnoid and parenchymal hemorrhage associated with cerebral contusion. Activated partial thromboplastin time upon admission ranged from 31.6 to 72.4s. After admission, systolic blood pressure in the 2 patients with intracerebral hemorrhage was maintained below 140 mmHg, and the subdural hematomas in 4 patients were surgically treated. None of the hematomas became enlarged and outcome was good in most cases.
  
  
  CONCLUSIONS
  Hematomas that arise due to acute intracranial bleeding during dabigatran treatment seem to remain small to moderate, hard to expand, and manageable.
authors.affiliation: Department of Cerebrovascular Medicine and Neurology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center.
authors.forename: Motohiro
authors.initials: M
authors.lastname: Komori
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yasaka
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Kokuba
authors.forename: Hideki
authors.initials: H
authors.lastname: Matsuoka
authors.forename: Shigeru
authors.initials: S
authors.lastname: Fujimoto
authors.forename: Megumu
authors.initials: M
authors.lastname: Yoshida
authors.forename: Katsuharu
authors.initials: K
authors.lastname: Kameda
authors.forename: Tadahisa
authors.initials: T
authors.lastname: Shono
authors.forename: Shinji
authors.initials: S
authors.lastname: Nagata
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ago
authors.forename: Takanari
authors.initials: T
authors.lastname: Kitazono
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Okada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D000069604:Dabigatran; D005260:Female; D006801:Humans; D020300:Intracranial Hemorrhages / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran